Fig 6.

KSHV protein expression in cells treated with TPA or the apoptosis inducer DCPE. ORF50ΔSTAD BCBL-1 cells were treated either with TPA to induce KSHV replication via the conventional pathway or with DCPE to induce apoptosis or left untreated. The cells were studied with confocal immunofluorescence microscopy using as the primary antibody a monoclonal antibody against KSHV ORF K8.1A, a well-characterized KSHV late gene whose product is associated with the plasma membrane (red – ORF K8.1 detected using an anti-ORF K8.1A mouse monoclonal antibody and an Alexa Fluor 687-conjugated goat anti-mouse secondary antibody). Cells were counterstained with DAPI (blue). Both positive-control TPA treatment and treatment with the apoptosis inducer DCPE resulted in high levels of expression of ORF K8.1A in essentially all of the treated cells.